Evolva appoints Norbert Bender as Chief Medical Officer

03-May-2011 - Switzerland

Evolva Holding SA  announced that it has appointed Norbert Bender, M.D, Ph.D., an experienced drug development professional, as its Chief Medical Officer (CMO) with immediate effect.

Norbert Bender is an M.D. from the University of Frankfurt, Germany and has a Ph.D. in Biochemistry and Pharmacy from the same institution.  He practiced for 10 years as a medical doctor in internal medicine at the Frankfurt University Hospital. He subsequently worked for more than 20 years in various senior functions in pharmaceutical (Hoechst, Knoll) and biotech companies (Cardion, Trigen, ViroLogik), in both Europe and North America.  Dr. Bender has particular expertise in the cardiovascular space and has been involved in the successful development of Ramipril and its fixed combinations, Reviparine, Sibutramine and Adalimumab. He will take the CMO post that has been vacant since the departure of Jessica Mann in 2010 and will be a member of the Group Management Team. He has been working as a medical consultant to Evolva since October 2010.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances